The first month and the month after, in one sentence
Halfway down the priced page, a paragraph states the first-month figure, the standing monthly figure it becomes, and the three-month plan rate, in that order, in a single sentence. That is the disclosure this whole category is built to avoid.
Twenty-three of the one hundred and fifty-eight sellers here publish an introductory rate at all, and most of the rest simply print the low number and let the reader find out. We have stored the introductory figure as an intro offer and the standing figure as the price row, so a comparison against the rest of the roster uses the number a buyer pays in month two.
The hero band disagrees
At the top of the same page, a band reads starting at a monthly figure, and immediately beneath it, same price, every dose. That figure is below the three-month rate and well below the standing rate.
There is no plan on the page that sells at it. We have put it in the qualifier of the standing price row rather than storing it, and we are not resolving the conflict. Seventy-eight of the one hundred and fifty-eight sellers here carry a headline figure that is promotional, introductory, or conditioned on something the number does not disclose.
Two clinicians, and a name that appears twice
The page names two clinicians with their specialties: a family-medicine physician and an emergency-medicine physician. Fifty of the one hundred and fifty-eight sellers here name an individual clinician.
One of those two names also appears, with the same credential, as the medical reviewer on the priced page of a different seller in this same batch of additions. We are recording that the same name appears on both sites and nothing more: a clinician can work with more than one telehealth service, and we have not established that these are the same person. What it does establish is that a named clinician is a weaker signal than it looks, in the same way that naming a pharmacy is weaker when a dozen brands name the same one.
The page states coverage in all fifty states in two places and we have recorded that. No compounding pharmacy is named: it says 503A licensed pharmacies and a pharmacy network, which is a category. One hundred and twenty-six of the one hundred and fifty-eight sellers here name none.
Heros Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $199/mothe standing monthly rate after a stated $149 first month; the hero band on the same page reads Starting at $119/mo, same price every dose, which no plan on the page sells at | September 2026source |
| Semaglutide (compounded) | $165/moper month on the 3-month plan, as stated on the same page beside the standing rate | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Heros Health's current price →Good fit if
- Readers who want the first month and the standing rate stated together, before they buy.
- Buyers who want a three-month rate priced beside the month-to-month one.
- People who want named clinicians with stated specialties.
- Anyone who needs a fifty-state coverage claim.
Look elsewhere if
- Anyone who reads a hero band as a price. This one advertises a flat rate no plan on the page sells at.
- Readers who want the compounding pharmacy named.
- Buyers who need the membership question answered.
- People who treat a named clinician as proof of an exclusive clinical relationship.
How this review was verified
- Re-read the weight-loss page and the privacy policy on 6 September 2026, comparing the requested path to the effective path and running a nonsense path against the host in the same run.
- Stored the introductory figure as an intro offer and the standing figure as the price row, so nothing on this site compares a first month against another seller's ongoing rate.
- Recorded the hero-band figure in the standing row's qualifier rather than storing it, and did not resolve the conflict between the two schemes.
- Checked the two clinician names against the other sellers added in this batch, and recorded the one that recurs as a recurrence of a name rather than as a claim about a person.
- Screened the operating entity and the brand name against FDA's live warning-letter record with a known letter as a positive control and a nonsense string as a negative control in the same pass. Neither returned a letter. Untitled letters are published separately and were not searched.